Novan announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration seeking marketing approval for berdazimer gel, 10.3% for the topical treatment of molluscum contagiosum. Assuming the filing is accepted by the FDA and given a typical 12-month review process, Novan anticipates a potential first quarter 2024 approval. Berdazimer gel, 10.3% is poised to be a first-in-class topical treatment for molluscum. The active ingredient, berdazimer sodium, is a new chemical entity that releases nitric oxide and has anti-viral activity. If approved, berdazimer gel, 10.3% would be the first effective and safe topical treatment indicated for molluscum with the convenience of self-application. Results from the pivotal Phase 3 B-SIMPLE4 clinical study evaluating berdazimer gel, 10.3% for the treatment of molluscumdemonstrated highly statistically significant improvement in primary clinical endpoint in the largest cohort of molluscum patients ever studied and were recently published in JAMA Dermatology. Berdazimer gel, 10.3% was found to be well tolerated with mild application site pain and mild to moderate erythema reported as the most common adverse events.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NOVN:
- Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
- Novan’s EPI Health enters exclusive license agreement with Sato for RHOFADE
- EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
- Novan’s EPI Health executes $15M financing agreement
- Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference